Search
Semaglutide Treatment Options
A collection of 191 research studies where Semaglutide is the interventional treatment. These studies are located in the United States . Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
1 - 12 of 191
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Recruiting
The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) distributed in various organs. These medications provide an average of 15-22% weight redu... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: The Cleveland Clinic, Cleveland, Ohio
Conditions: Obesity and Obesity-related Medical Conditions
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
Completed
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in di... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Type 2 Diabetes
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Active Not Recruiting
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease ris... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Case Western Reserve University, Cleveland, Ohio +1 locations
Conditions: HIV/AIDS, Lipohypertrophy, Obesity
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Recruiting
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
08/08/2025
Locations: Neighborhood Healthcare, Escondido, California +100 locations
Conditions: Obesity
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
Completed
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/04/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Recruiting
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/01/2025
Locations: The University of Arizona College of Medicine- Phoenix, Phoenix, Arizona +1 locations
Conditions: Overweight or Obesity, Atrial Fibrillation
Semaglutide Therapy for Alcohol Reduction (STAR)
Recruiting
Background:
Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed.
Objective:
To test if a medication named Semaglutide is safe and may reduce alcohol drinking in people with AUD.
Who can participate?
All Adults aged 18 or older with AUD might be eligible to participate in the study.
What will... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
07/31/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Addiction, Alcohol Use Disorder
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Recruiting
Background:
In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
Objective:
To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide.
Eligibility:
People with NAFLD and healthy volunteers ages 18 and older
Design:
Participants will be screened with:
Medical history
Physical exam... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Active Not Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Univ of Alabama_Birmingham, Birmingham, Alabama +175 locations
Conditions: Type 2 Diabetes
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active Not Recruiting
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSem... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +225 locations
Conditions: Obesity
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Completed
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: John Muir Physicians Network, Concord, California +174 locations
Conditions: Overweight, Obesity, Type 2 Diabetes Mellitus
1 - 12 of 191